Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Status Recruiting

Clinical Trial Summary

This randomized clinical trial studies how well online genetics educational video with or without pre- and/or post-telephone genetics counseling works in assessing cancer-risk distress in patients with triple negative breast cancer. Online genetic education and telephone genetic counseling may help the doctors learn the stress a person feels about their risk of cancer.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To test the effects of online genetic education versus telephone genetic counseling on cancer-risk distress. SECONDARY OBJECTIVES: I. To test the effects of online genetic education versus telephone genetic counseling on testing completion rates. II. To evaluate the role of psychological and social variables in women's reactions to genetic testing for ovarian cancer risk with variable education strategies. III. To consider the effects of variations of genetic education/counseling on genetic knowledge, satisfaction with the decision to undergo testing, and family communication. OUTLINE: Patients are randomized into 1 of 4 arms. ARM A: Patients watch genetic testing online educational video and receive genetic testing online test results report. ARM B: Patients watch genetic testing online educational video, receive genetic testing online test results report, and post-telephone genetic counseling. ARM C: Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, genetic testing online test results report, and post-telephone genetic counseling. ARM D: Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, and genetic testing online test results report. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02993068
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact	Karen H. Lu, MD
Phone	713-745-7877
Email	magenta@mdanderson.org
Status	Recruiting
Phase	N/A
Start date	April 18, 2017
Completion date	April 18, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03156309` - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission	Phase 1
Completed	`NCT01928186` - FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer	N/A
Active, not recruiting	`NCT02780401` - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission	Phase 1
Terminated	`NCT02892734` - Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer	Phase 2
Recruiting	`NCT03723928` - S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer	N/A
Completed	`NCT00390455` - Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive	Phase 3
Recruiting	`NCT03213041` - Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer	Phase 2
Withdrawn	`NCT03238703` - Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer	Phase 4
Active, not recruiting	`NCT02876107` - Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer	Phase 2
Terminated	`NCT01957514` - Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy
Terminated	`NCT01149356` - RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer	Phase 1
Active, not recruiting	`NCT02445391` - Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy	Phase 3
Completed	`NCT01964924` - Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	Phase 2
Terminated	`NCT03070002` - Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells	Phase 2
Completed	`NCT00785291` - Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer	Phase 3
Completed	`NCT02120469` - Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer	Phase 1
Active, not recruiting	`NCT02744053` - DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer	Early Phase 1
Terminated	`NCT01071564` - RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery	Phase 1
Active, not recruiting	`NCT03359954` - Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer	Phase 2
Completed	`NCT01251874` - Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer	Phase 1